Core Insights - Nanobiotix has been admitted to the CAC Mid 60 and SBF 120 indices following the annual review of the Euronext Paris indices, effective after market close on December 19, 2025, which is expected to enhance its visibility among institutional investors and strengthen its presence in European equity markets [1][2]. Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on physics-based therapeutic approaches aimed at improving treatment outcomes for cancer and other major diseases [1][4]. - The company is headquartered in Paris, France, and has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020 [5]. Strategic Significance - The inclusion in the CAC Mid 60 and SBF 120 indices reflects the financial markets' confidence in Nanobiotix's long-term strategy and the potential of its nanotherapeutic solutions [3]. - The company aims to create sustainable value for patients, partners, and shareholders while advancing toward key milestones in physics-based medicine [3]. Intellectual Property - Nanobiotix holds over 25 umbrella patents related to three nanotechnology platforms, which have applications in oncology, bioavailability and biodistribution, and disorders of the central nervous system [6].